BIOPHTA Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $7.03M

  • Investors
  • 13

BIOPHTA General Information

Description

Developer of ophthalmic pharmaceutical treatments designed to improve the efficacy of retinal disease therapies and reduce reliance on eye drops and intraocular injections. The company offers once-weekly, non-invasive topical treatments, including a glaucoma therapy and an anti-vascular endothelial growth factor treatment for diabetic retinopathy, enabling patients and healthcare providers to manage retinal and other eye conditions through less invasive treatment options.

Contact Information

Website
www.biophta.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Le Biopôle
  • 6, rue Pierre Joseph Colin
  • 35000 Rennes
  • France
+33 06
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Biotechnology
Corporate Office
  • Le Biopôle
  • 6, rue Pierre Joseph Colin
  • 35000 Rennes
  • France
+33 06

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BIOPHTA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. Seed Round 01-Jun-2024 $7.03M Completed Generating Revenue
8. Accelerator/Incubator 12-May-2022 Completed Generating Revenue
7. Accelerator/Incubator 01-Jan-2022 Completed Generating Revenue
6. Angel (individual) 28-May-2021 Completed Generating Revenue
5. Accelerator/Incubator 01-Jan-2021 Completed Pre-Clinical Trials
4. Accelerator/Incubator Completed Generating Revenue
3. Accelerator/Incubator 18-Oct-2020 Completed Pre-Clinical Trials
2. Accelerator/Incubator 02-Jun-2020 $54.6K $54.6K Completed Pre-Clinical Trials
1. Accelerator/Incubator 16-Mar-2020 Completed Pre-Clinical Trials
To view BIOPHTA’s complete valuation and funding history, request access »

BIOPHTA Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
AP Seed 2
Ordinary Shares
To view BIOPHTA’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

BIOPHTA Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of ophthalmic pharmaceutical treatments designed to improve the efficacy of retinal disease therapies and redu
Drug Delivery
Rennes, France
7 As of 2026

Heidelberg, Germany
 

Zug, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BIOPHTA Competitors (2)

One of BIOPHTA’s 2 competitors is Novaliq, a Venture Capital-Backed company based in Heidelberg, Germany.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novaliq Venture Capital-Backed Heidelberg, Germany
Oculis Holding Formerly VC-backed Zug, Switzerland
You’re viewing 2 of 2 competitors. Get the full list »

BIOPHTA Patents

BIOPHTA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2022323447-A1 Mucoadhesive ocular delivery system for the treatment of glaucoma Pending 03-Aug-2021
CA-3227607-A1 Mucoadhesive ocular delivery system for the treatment of glaucoma Pending 03-Aug-2021
EP-4380545-A1 Mucoadhesive ocular delivery system for the treatment of glaucoma Pending 03-Aug-2021
US-20240335375-A1 Mucoadhesive ocular delivery system for the treatment of glaucoma Pending 03-Aug-2021
WO-2023012239-A1 Mucoadhesive ocular delivery system for the treatment of glaucoma Inactive 03-Aug-2021 A61K9/0048
To view BIOPHTA’s complete patent history, request access »

BIOPHTA Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BIOPHTA Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Elaia Partners Venture Capital Minority
GO Capital Venture Capital Minority
HTL Biotechnology PE-Backed Company Minority
Merieux Equity Partners (Lyon) PE/Buyout Minority
UI Investissement PE/Buyout Minority
You’re viewing 5 of 13 investors. Get the full list »

BIOPHTA FAQs

  • When was BIOPHTA founded?

    BIOPHTA was founded in 2020.

  • Where is BIOPHTA headquartered?

    BIOPHTA is headquartered in Rennes, France.

  • What is the size of BIOPHTA?

    BIOPHTA has 7 total employees.

  • What industry is BIOPHTA in?

    BIOPHTA’s primary industry is Drug Delivery.

  • Is BIOPHTA a private or public company?

    BIOPHTA is a Private company.

  • What is the current valuation of BIOPHTA?

    The current valuation of BIOPHTA is .

  • What is BIOPHTA’s current revenue?

    The current revenue for BIOPHTA is .

  • How much funding has BIOPHTA raised over time?

    BIOPHTA has raised $8.4M.

  • Who are BIOPHTA’s investors?

    Elaia Partners, GO Capital, HTL Biotechnology, Merieux Equity Partners (Lyon), and UI Investissement are 5 of 13 investors who have invested in BIOPHTA.

  • Who are BIOPHTA’s competitors?

    Novaliq and Oculis Holding are competitors of BIOPHTA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process